- Home
- CDIO vs CERO Comparison
CDIO vs CERO Comparison
Compare CDIO & CERO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CDIO
- CERO
- Stock Information
- Founded
- CDIO 2017
- CERO 2017
- Country
- CDIO United States
- CERO United States
- Employees
- CDIO N/A
- CERO N/A
- Industry
- CDIO Biotechnology: Commercial Physical & Biological Resarch
- CERO
- Sector
- CDIO Health Care
- CERO
- Exchange
- CDIO Nasdaq
- CERO Nasdaq
- Market Cap
- CDIO 6.4M
- CERO 5.6M
- IPO Year
- CDIO N/A
- CERO N/A
- Fundamental
- Price
- CDIO $3.86
- CERO $5.63
- Analyst Decision
- CDIO
- CERO Strong Buy
- Analyst Count
- CDIO 0
- CERO 2
- Target Price
- CDIO N/A
- CERO $45.00
- AVG Volume (30 Days)
- CDIO 21.5K
- CERO 306.0K
- Earning Date
- CDIO 11-12-2025
- CERO 08-22-2025
- Dividend Yield
- CDIO N/A
- CERO N/A
- EPS Growth
- CDIO N/A
- CERO N/A
- EPS
- CDIO N/A
- CERO N/A
- Revenue
- CDIO $19,507.00
- CERO N/A
- Revenue This Year
- CDIO $1,434.82
- CERO N/A
- Revenue Next Year
- CDIO $4,661.91
- CERO N/A
- P/E Ratio
- CDIO N/A
- CERO N/A
- Revenue Growth
- CDIO N/A
- CERO N/A
- 52 Week Low
- CDIO $3.22
- CERO $4.27
- 52 Week High
- CDIO $53.10
- CERO $895.40
- Technical
- Relative Strength Index (RSI)
- CDIO 51.46
- CERO 35.75
- Support Level
- CDIO $3.58
- CERO $5.29
- Resistance Level
- CDIO $3.98
- CERO $5.65
- Average True Range (ATR)
- CDIO 0.23
- CERO 0.54
- MACD
- CDIO 0.03
- CERO -0.12
- Stochastic Oscillator
- CDIO 66.67
- CERO 36.61
About CDIO Cardio Diagnostics Holdings Inc. Common stock
Cardio Diagnostics Holdings Inc is a medical technology company focused on developing and commercializing epigenetics-based clinical tests for cardiovascular diseases. The company offers three AI-powered solutions for the risk assessment, detection, management, and monitoring of coronary heart diseases. These solutions are Epi+Gen CHD, a symptomatic CHD risk assessment clinical blood test targeting CHD events; PrecisionCHD, an integrated epigenetic-genetic clinical blood test for the detection of coronary heart disease; and Actionable Clinical Intelligence, a platform coupled to the Epi+Gen CHD and PrecisionCHD tests that provide personalized insights by linking the epigenetic and genetic biomarkers evaluated by these tests to the drivers of coronary heart disease.
About CERO CERo Therapeutics Holdings Inc. Common Stock
CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy. Its lead molecule is CER-1236, an autologous T-cell product that targets a novel tumor antigen, TIM-4 ligand.